GON Stock Overview
A late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Geron Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.20 |
| 52 Week High | US$5.20 |
| 52 Week Low | US$1.58 |
| Beta | 0.52 |
| 1 Month Change | -16.11% |
| 3 Month Change | -18.54% |
| 1 Year Change | 64.93% |
| 3 Year Change | 178.09% |
| 5 Year Change | 174.51% |
| Change since IPO | -63.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| GON | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.4% | 3.1% | 0.5% |
| 1Y | 64.9% | -13.8% | 7.2% |
Return vs Industry: GON exceeded the German Biotechs industry which returned -14.5% over the past year.
Return vs Market: GON exceeded the German Market which returned 7% over the past year.
Price Volatility
| GON volatility | |
|---|---|
| GON Average Weekly Movement | 5.3% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GON has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: GON's weekly volatility has decreased from 15% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 141 | Chip Scarlett | www.geron.com |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation Fundamentals Summary
| GON fundamental statistics | |
|---|---|
| Market cap | €1.91b |
| Earnings (TTM) | -€192.96m |
| Revenue (TTM) | €28.27m |
68.7x
P/S Ratio-10.1x
P/E RatioIs GON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GON income statement (TTM) | |
|---|---|
| Revenue | US$29.48m |
| Cost of Revenue | US$112.38m |
| Gross Profit | -US$82.90m |
| Other Expenses | US$118.29m |
| Earnings | -US$201.19m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | -281.22% |
| Net Profit Margin | -682.47% |
| Debt/Equity Ratio | 28.7% |
How did GON perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 00:19 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Geron Corporation is covered by 29 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Carter Gould | Barclays |
| Peter Lawson | Barclays |
| George Zavoico | B. Riley Securities, Inc. |